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REPLY
We thank Drs. Arques and Roux for their comments concerning
the increasing use of the deceleration time of the pulmonary
venous early diastolic flow (PV-DT) in published reports. We
agree that the PV-DT is a useful tool for estimating pulmonary
capillary wedge pressure (PCWP) as a measure of the left ventric-
ular (LV) filling pressure, especially in patients with normal sinus
rhythm. As mentioned in our study (1), it is important to recognize
the influence of several factors regarding use of pulmonary venous
flow velocities in clinical practice.
When evaluating PV-DT to estimate PCWP, the influences of
heart rate, mitral regurgitation (MR), atrial fibrillation (AF), and
LV systolic function have to be taken into account. Of those
factors, heart rate may have the largest influence on the PV-DT.
Chirillo et al. (2) specifically paid attention to the two components
of the deceleration slope of PV-DT. They speculated that the first
component was mainly dependent on the initial driving pressure of
the pulmonary venous flow, and the second component was
affected by the duration of LV relaxation, LV compliance, and
heart rate as reported by Little et al. (3). They found a strong
correlation between the initial deceleration slope of PV-DT and
PCWP during chronic AF with controlled ventricular rates. With
faster heart rates, it would be difficult to separate the first and
second components. Thus, PV-DT can estimate PCWP only
when the heart rates are relatively slow. Matsukida et al. (4) have
also reported that the PV-DT accurately predicted PCWP in
patients with AF, whereas they only included patients with a heart
rate of 60 to 80 beats/min. Both of the above investigators (2,4)
excluded patients with AF and a rapid ventricular rate. It is well
recognized that the loading conditions during AF are constantly
changing; therefore, even when an average of consecutive several
cardiac cycles of PV-DT is used, the value would vary depending
on the selected beats.
The final issue is the effect of MR. Pozzoli et al. (5) reported
that the PCWP can be reliably estimated by combining mitral
inflow and pulmonary venous flow velocities even when MR was
present. Although they have not evaluated PV-DT, the investiga-
tors have reported that the correlation between mitral deceleration
time and PCWP was stronger in patients without MR. Further-
more, they have limited their results to apply to patients without
atrial arrhythmias or tachycardia.
Thus, we conclude that the evaluation of the PV-DT for
estimating PCWP is most useful in patients without MR with
sinus rhythm and a relatively slower heart rate. As suggested by
Drs. Arques and Roux, we believe that the improvement in the
quality of pulmonary venous Doppler flow profile obtained by
transthoracic techniques will enhance the future use of PV flow in
clinical practice.
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Glycoprotein IIb/IIIa Inhibitors
and the Guidelines for Treatment of
Non–ST-Elevation Myocardial Infarction
In a recent study published in the Journal (1) Peterson et al. found
that with regard to use of glycoprotein (GP) IIb/IIIa inhibitors
there was a low adherence to American College of Cardiology/
American Heart Association guidelines (published in 2000) for
treatment of non–ST-elevation myocardial infarction (2), and they
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noted that increased use of this type of medication represents a
target for quality improvement. The observation that most clini-
cians were not implanting recommendations from published
guidelines is important, but conclusions regarding specific use of
GP IIb/IIIa inhibitors are limited by the fact that the guidelines
referenced in this study have already been superseded by new
guidelines published in 2002 (3), which incorporate research
showing the importance of adding clopidogrel to aspirin early in
the treatment of acute coronary syndromes (4).
The role of GP IIb/IIIa inhibitors for treatment of acute
coronary syndromes at this time is not clear. Therapy with
clopidogrel has not been compared directly to therapy with GP
IIb/IIIa inhibitors, and further data need to be obtained to
determine the incremental value for adding GP IIb/IIIa inhibitors
to aspirin/clopidogrel/heparin therapy (5). Recommendations may
differ in patients with different prognostic risk (as assessed by
clinical/laboratory variables at time of initial presentation) and
whether an interventional or noninterventional approach is being
used. In many cases, GP IIb/IIIa inhibitors may be a fourth
element of antiplatelet/antithrombotic therapy to consider in
patients with acute coronary syndromes.
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REPLY
Dr. Coplan questions the evidence supporting glycoprotein (GP)
IIb/IIIa inhibitors in the care of non–ST-elevation acute coronary
syndrome (ACS). This doubt is remarkable given that GP IIb/IIIa
agents have received more intensive investigation than nearly any
other ACS treatment. More than 30,000 patients have been
studied in six randomized trials of GP IIb/IIIa inhibitors. Three
meta-analyses have summarized the trial results, each concluding
that early use of GP IIb/IIIa agents resulted in a highly significant
overall reduction in risk for death or myocardial infarction (1–3).
Dr. Coplan is correct that the benefits tended to be greater in those
patients with higher risk (as marked by positive cardiac markers,
ST depression, or patients selected for interventional procedures,
or those with other high-risk clinical features such as diabetes
mellitus, heart failure, or advanced age). These findings are similar
to those seen for many ACS interventions and argue for appro-
priate risk-based treatment strategies. Based on these findings,
both the 2000 American College of Cardiology/American Heart
Association Guidelines and the current 2002 Guidelines Update
recommend the use of GP IIb/IIIa inhibitors in high-risk ACS
patients (4,5). To this body of knowledge, our current study
provided further confirmatory evidence that early use of GP
IIb/IIIa inhibitors was associated with significantly lower in-
hospital mortality rates when used in a community-based non–
ST-elevation patient population. These benefits were also seen in
all patient subgroups including those receiving conservative, non-
interventional care (6).
Dr. Coplan is correct that there are limited randomized trial
data on the incremental value of other antiplatelet therapies (such
as clopidogrel) in patients already receiving a GP IIb/IIIa agent or
vice versa. However, in the absence of data, one cannot conclude
which agent is superior and/or whether a combined approach may
yield the best results. Specifically, use of intravenous (IV) GP
IIb/IIIa inhibitors results in much more rapid and complete
inhibition of platelet aggregation than an oral inhibitor such as
clopidogrel. Yet clopidogrel can be continued after IV GP IIb/IIIa
agents have been discontinued and still provide long-term benefits
(in combination with aspirin) in patients with coronary disease (7).
Whether first, second, third, or “fourth,” we would hope that
clinicians would use all guidelines-indicated therapies to improve
the outcomes of patients with ACS.
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